DFE Pharma Launches BioHale® Trehalose to offer Pharma customers increased stability in Biologics

DFE Pharma Launches BioHale® Trehalose to offer Pharma customers increased stability in Biologics

With BioHale® Trehalose, the latest addition to the BioHale® portfolio line, DFE Pharma expands its offering of stabilizers for biologics while providing further security of supply.

Goch, Germany (15 September 2021) – DFE Pharma, a global leader in pharmaceutical excipient solutions, announced the expansion of its platform of stabilizers for biologics with the launch of BioHale® Trehalose. 

It’s critical for pharma companies to maintain an ensured supply in their formulation processes for efficacious delivery of biologics. DFE Pharma provides security of supply, to meet its customers’ demands in order to moving to a healthier world.

Trehalose – developed to meet the highest quality standards - can be used in parenteral formulations, but is also part of inhalation pipeline projects.  The specifications meet requirements of all relevant pharmacopoeias including EU, US, Japan and China.

“With this launch, we are continuing our approach to offer our pharma customers a platform of stabilizers for biologics. Next to BioHale Sucrose, our Trehalose further supports customers to choose what stabilizer works best in their individual biopharmaceutical formulation”, comments Bas van Driel, CEO of DFE Pharma.

To find out more on DFE Pharma’s BioPharma portfolio, visit Biopharma | DFE Pharma